Course: Advancing Equity in Relapsed/Refractory Multiple Myeloma: Integrating Emerging?CELMoD?Therapies Into Community Oncology Practice
CME Credits: 1.00
Released: 2026-07-31
Multiple novel targets and agents are currently being evaluated for relapsed/refractory multiple myeloma (RRMM), including triple-class refractory disease and beyond. Among the most promising are cereblon E3 ligase modulators (CELMoDs). Early-phase clinical trials have demonstrated manageable safety profiles and encouraging activity in heavily pretreated and triple-class refractory patients, supporting their potential therapeutic role in RRMM. However, access to these treatments can be limited, particularly in community-based settings that face oncology specialist shortages, long travel times to care, limited insurance coverage, and low participation in clinical trials. This online, on-demand CME/CE activity will review CELMoDs for RRMM, including emerging clinical evidence and the role of these therapies in treatment decision-making. Methods to increase patient access to emerging therapies and clinical trials in community-based settings will also be discussed. This enduring activity is a recorded session from Oncology Congress that took place on June 13, 2026.
Upon completion of this activity, participants should be better able to:
View Full Course